Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1327-1328

  Eckrich, Michael J ^a   Domm, Jennifer ^a   Ho, Richard ^a   Whitlock, James A ^a   Frangoul, Haydar ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Autologous transplant; Down syndrome; Hodgkin disease

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; NAVELBINE; PREDNISONE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT; CVPPABO PROTOCOL; DOXORUBICIN; DRUG DERIVATIVE; VINBLASTINE;

ANAMNESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOWN SYNDROME; ERYTHROCYTE SEDIMENTATION RATE; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; LYMPH NODE HYPERPLASIA; LYMPHADENECTOMY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD; SPLENOMEGALY; TREATMENT DURATION; TREATMENT RESPONSE; AUTOTRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENT DISEASE; REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARMUSTINE; CHILD; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOWN SYNDROME; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY-STIMULATING FACTOR; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; MALE; MESNA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROCARBAZINE; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VINBLASTINE; VINCRISTINE;

EID: 70449700179     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22182     Document Type: Article

References (20)

1. Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006;135:595-602.
2. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165-169.
3. Patja K, Pukkala E, Sund R, et al. Cancer incidence of persons with Down syndrome in Finland:Apopulation-based study. Int J Cancer 2006;118:1769-1772.
4. McCormick DP, Meyer WJ, Nesbit ME. Coexistence of Hodgkin's disease and Down's syndrome. Am J Dis Child 1971;122:71-73.
5. Gurjal A, Rao S, Gladstone B, et al. Down's syndrome with Hodgkin's disease. Indian Pediatr 1993;30:684-687.
6. Sandoval C, Hudson MM, Ozkaynak MF, et al. Down syndrome and Hodgkin disease in childhood. Med Pediatr Oncol 2000;34:304-305.
7. Magagnoli M, Balzarotti M, Castagna L, et al. What is the best option to cure patients with resistant/relapsing Hodgkin's disease? Curr Stem Cell Res Ther 2006;1:419-424.
8. Moskowitz C. An update on the management of relapsed and primary refractory Hodgkin's disease. Semin Oncol 2004;31:54-59.
9. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-3771.
10. Garre ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987;111:606-612.
11. Whitlock JA, Sather HN, Gaynon P, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2005;106:4043-4049.
12. Holland WW, Doll R, Carter CO. The mortality from leukaemia and other cancers among patients with Down's syndrome (mongols) and among their parents. Br J Cancer 1962;16:177-186.
13. Baird PA, Sadovnick AD. Causes of death to age 30 in Down syndrome. Am J Hum Genet 1988;43:239-248.
14. Scholl T, Stein Z, Hansen H. Leukemia and other cancers, anomalies and infections as causes of death in Down's syndrome in the United States during 1976. Dev Med Child Neurol 1982;24:817-829.
15. Shen JJ, Williams BJ, Zipursky A, et al. Cytogenetic and molecular studies of Down syndrome individuals with leukemia. Am J Hum Genet 1995;56:915-925.
16. Fargnoli MC, Peris K, Frascione P, et al. Psoriasis, Kaposi's sarcoma and Hodgkin's disease in a patient with Down's syndrome. Dermatology 2004;209:158-159.
17. Kusumakumary P, Jyothirmayi R, Chellam VG, et al. Hodgkin's disease in association with Down syndrome: A case report. Pediatr Hematol Oncol 1996;13:469-471.
18. Satge D, Sasco AJ, Chompret A, et al. A 22-year French experience with solid tumors in children with Down syndrome. Pediatr Hematol Oncol 2003;20:517-529.
19. Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 1998;103:533-535.
20. Meissner B, Borkhardt A, Dilloo D, et al. Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. Bone Marrow Transplant 2007;40:945-949.